BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27991896)

  • 1. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.
    Perez LE; Fernandez H; Ayala E; Beato F; Neuger A; Pidala J; Schell MJ; Anasetti C
    Bone Marrow Transplant; 2017 Apr; 52(4):627-629. PubMed ID: 27991896
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.
    Kim TK; DeVeaux M; Stahl M; Perreault S; Isufi I; Cooper D; Foss F; Shlomchik W; Zelterman D; Zeidan AM; Seropian S
    Ann Hematol; 2019 Jan; 98(1):237-240. PubMed ID: 30027436
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
    Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.
    Sakai R; Taguri M; Oshima K; Mori T; Ago H; Adachi S; Morita S; Taniguchi S; Fukuda T; Ohashi K; Eto T; Miyamura K; Iwato K; Kobayashi N; Kanamori H; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M
    Int J Hematol; 2016 Mar; 103(3):322-33. PubMed ID: 26800676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
    Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA
    Bone Marrow Transplant; 2017 Mar; 52(3):438-444. PubMed ID: 27819684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
    Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
    Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
    Kanate AS; Hari PN; Pasquini MC; Visotcky A; Ahn KW; Boyd J; Guru Murthy GS; Rizzo JD; Saber W; Drobyski W; Michaelis L; Atallah E; Carlson KS; D'Souza A; Fenske TS; Cumpston A; Bunner P; Craig M; Horowitz MM; Hamadani M
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1295-1302. PubMed ID: 28412518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.
    Armand P; Kim HT; Sainvil MM; Lange PB; Giardino AA; Bachanova V; Devine SM; Waller EK; Jagirdar N; Herrera AF; Cutler C; Ho VT; Koreth J; Alyea EP; McAfee SL; Soiffer RJ; Chen YB; Antin JH
    Br J Haematol; 2016 Apr; 173(1):96-104. PubMed ID: 26729448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors.
    Hagen PA; Adams W; Smith S; Tsai S; Stiff P
    Bone Marrow Transplant; 2019 Jan; 54(1):155-158. PubMed ID: 30038351
    [No Abstract]   [Full Text] [Related]  

  • 14. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
    Przepiorka D; Khouri I; Ippoliti C; Ueno NT; Mehra R; Körbling M; Giralt S; Gajewski J; Fischer H; Donato M; Cleary K; Claxton D; Chan KW; Braunschweig I; van Besien K; Andersson BS; Anderlini P; Champlin R
    Bone Marrow Transplant; 1999 Oct; 24(7):763-8. PubMed ID: 10516680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
    Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
    Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
    Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
    Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V
    Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.